Viridian Therapeutics Inc Ordinary Shares VRDN 深 沪
已收盘 08-01 16:00:00 美东时间
17.41
-0.110
-0.63%
华盛通- 最 高17.66
- 今 开17.32
- 成交量 66.26万股
- 最 低 17.05
- 昨 收 17.52
- 总市值 14.21亿
- 52周最高 27.20
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 9.90
- 委 比 -87.36%
- 总股本 8159.20万
- 历史最高 270.00
- 量 比 0.93
- 振 幅 3.48%
- 历史最低 4.665
- 每 手 1
- 风险率 3.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Viridien: Information on the total number of voting rights and shares
Viridien, a French société anonyme with a capital of €7,180,449, headquartered in Massy, France, reported its voting rights and share information as of July 31, 2025. The total issued shares were 7,180,449, with actual voting rights at 7,213,469 and theoretical voting rights at 7,213,718. Shares held for over two years carry double voting rights, while treasury shares have no voting rights. The figures comply with French Commercial Code and AMF r...
08-01 08:23
Viridian Therapeutics Partners with Kissei for Japan Market
Viridian Therapeutics ( ($VRDN) ) just unveiled an announcement. On July 30, 20...
07-30 19:29
Viridian Therapeutics Stockholders Approve Key Proposals
Viridian Therapeutics ( ($VRDN) ) has shared an announcement. At the Annual Mee...
06-25 04:52
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
Viridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients
- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 -- Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting
05-20 19:06
Viridian Metals Secures Oversubscribed Financing for Critical Metals Exploration
Viridian Metals Inc ( ($TSE:VRDN) ) has provided an announcement. Viridian Meta...
05-14 23:07
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
In the preceding three months, 5 analysts have released ratings for Viridian Th...
05-08 06:00
Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $36
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $38 to $36.
05-07 19:56
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif., April 29, 2025 /PRNewswire/ -- Dynavax Technologi...
04-29 19:30
